Advertisement

Topics

PubMed Journals Articles About "Test Results After Stem Cell Transplant Multiple Myeloma" RSS

12:29 EST 14th December 2018 | BioPortfolio

Test Results After Stem Cell Transplant Multiple Myeloma PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Test Results After Stem Cell Transplant Multiple Myeloma articles that have been published worldwide.

More Information about "Test Results After Stem Cell Transplant Multiple Myeloma" on BioPortfolio

We have published hundreds of Test Results After Stem Cell Transplant Multiple Myeloma news stories on BioPortfolio along with dozens of Test Results After Stem Cell Transplant Multiple Myeloma Clinical Trials and PubMed Articles about Test Results After Stem Cell Transplant Multiple Myeloma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Test Results After Stem Cell Transplant Multiple Myeloma Companies in our database. You can also find out about relevant Test Results After Stem Cell Transplant Multiple Myeloma Drugs and Medications on this site too.

Showing "Test results after stem cell transplant multiple myeloma" PubMed Articles 1–25 of 68,000+

Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.

Autologous hematopoietic stem cell transplant (aHSCT) is an efficacious treatment for newly diagnosed multiple myeloma patients. However, as rapid advances have resulted in other highly efficacious and less intensive therapies, the role of aHSCT has been questioned.


Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma.

Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database.

Autologous hematopoietic stem cell transplantation (AHCT) is the standard of care for eligible multiple myeloma (MM) patients. We aim to explore disparities in hospital cost and in-hospital mortality among MM patients who received AHCT.


Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma-Reply.

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.

Maintenance (MT) may be prescribed after autologous stem cell transplant (ASCT) but there are often concerns about the impact on quality of life (QoL). QoL was compared between baseline patients (30-100 days post-ASCT and had not commenced MT); MT patients (>100 days post-ASCT and receiving MT), and no MT (>100 days post-ASCT and not receiving MT). Patients completed the EuroQoL five dimension (EQ-5D), the European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30), ...

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who are eligible for the procedure, and has contributed to improved overall survival. In the current era of novel therapies, the treatment landscape and prognosis have changed. The outstanding efficacy seen with regimens based on novel agents has led to a questioning of the frontline treatment paradigm with respect to ASCT. A key current question i...

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.

Triplets with immunomodulators (IMIDs) and proteasome inhibitors (PIs) improve overall survival (OS) in trials of newly diagnosed multiple myeloma (NDMM) patients although reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM patients in the USA by use of triplet vs doublet frontline therapy (FT).

Tenofovir Alafenamide Associated Fatal Lactic Acidosis in an Autologous Hematopoietic Stem Cell Transplant Recipient.

Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogs (NA) for the treatment of hepatitis B, C and HIV. No cases of such a complication have been reported in hematopoietic stem cell transplant (HSCT) recipients. We present a 65-year male who underwent autologous HSCT for the treatment of multiple myeloma. Prior to transplant he was started on single agent tenofovir alafenamide (TAF) for treatment of resolved hepatitis B infection. He presented few weeks later with...

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring salvage therapies, which results in cumulative immunosuppression. The impact of novel therapies on the immune system differs from that of traditional chemotherapy, and their application leads to emergence of infections not previously associated with myeloma, cytomegalovirus (CMV) infection being one of them(1). ...

Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.

The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and hematopoietic stem cell transplantation (HSCT), as well as disease progression and progression-free survival in multiple myeloma (MM) patients, thus becoming a tool of personalized medicine.

Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.

The revised International Staging System (R-ISS) and the International Myeloma Working Group 2014 (IMWG 2014) are newer staging systems used to prognosticate multiple myeloma (MM) outcomes. We hypothesized that these would provide better prognostic differentiation for newly diagnosed multiple myeloma (MM) compared to ISS. We analyzed the Center for International Blood and Marrow Transplant Research database from 2008-2014 to compare the 3 systems (N=628) among newly diagnosed MM undergoing upfront AHCT. The...

Cutaneous amyloidosis light-chain amyloidosis with multiple myeloma: A concise review.

Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well defined. The recently developed highly efficacious MM therapy has brought on a new set of challenges to this field for consideration. The goal of this paper is to describe the characteristics of cutaneous manifestations of systemic AL amyloidosis associated with MM according to age, sex, race, Ig type, plasma cell percentage, and cytogenetic and fluorescent...

Eculizumab for Transplant-Associated Thrombotic Microangiopathy in Adult Allogeneic Stem Cell Transplant Recipients.

To evaluate response rates and survival in adults with transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic stem cell transplantation (HSCT) who were treated with eculizumab (ECU).

Autologous Stem Cell Transplantation for Multiple Myeloma: Underutilized but Highly Effective.

Multiple Myeloma - Current Standards in Surgical Treatment.

Multiple myeloma is a haematological blood cancer in elderly patients, in which neoplastic cell populations cause osteolytic destruction in the bone skeleton. More than 50% of all patients sustain pathological fractures during the course of their disease. Of all malignant lesions of the spine, multiple myeloma is the most frequent spinal tumour and accounts for approximately 15% of all cases. 8 - 10% of the patients develop neurological deficits. In addition to systemic antineoplastic therapy, surgical ...

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Novel efficacious treatments with long-term tolerability are needed for transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. This phase 2 study evaluated the safety and efficacy of all-oral ixazomib-cyclophosphamide-dexamethasone (ICd) followed by single-agent ixazomib maintenance.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resistance.

Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.

Several studies demonstrate that the bromodomain inhibitor OTX015 has an anti-tumor activity in cancers. However, translation of these data to molecules suitable for clinical development has not yet to be accomplished in multiple myeloma (MM). Here, we identified genes and biologic processes which substantiated the anti-myeloma activity of OTX015 with global transcriptomics. OTX015 exerted a strong anti-proliferative effect and induced cell cycle arrest in vitro. Gene expression profiling uncovered that OTX...

Dual inhibition of EZH1/2 over-activates WNT signaling to deplete cancer stem cells in multiple myeloma.

Multiple myeloma (MM) is an incurable hematological malignancy caused by accumulation of abnormal clonal plasma cells. Despite the recent development of novel therapies, relapse of MM eventually occurs due to a remaining population of drug-resistant myeloma stem cells. Side population (SP) cells exhibit cancer stem cell-like characteristics in MM; thus targeting these cells is a promising strategy to completely cure this malignancy. Here, we showed that SP cells expressed higher levels of enhancer of zeste ...

High Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

Autologous stem cell transplantation (SCT) is the standard of care for all transplant eligible patients diagnosed with multiple myeloma (MM). Various studies have compared clinical outcomes with frontline SCT ("Early SCT") versus standard dose therapy (SDT) alone, with or without salvage SCT ("SDT/ late SCT"). In this meta-analysis, we compare overall survival (OS) and progression free survival (PFS) outcomes with these two treatment approaches. Twelve studies were identified, including 3,633 patients, of w...

Longitudinal flow cytometry identified "minimal residual disease" (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma.

Many questions about "minimal residual disease" (MRD) still need to be answered for multiple myeloma (MM). Flow MRD were monitored in 104 consecutive patients with MM after induction and at the 3, 6, 9, 12, 18, and 24 months post-transplant. Four MRD evolution patterns were revealed: pattern 1 patients had persistent MRD-negative after post-induction with no progression; pattern 2 patients had MRD-positive status post-induction but became MRD negative within 24 months post-transplant; pattern 3 patients had...

Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.

High-dose melphalan (HDM) is part of the conditioning regimen in patients with multiple myeloma (MM) receiving autologous stem cell transplantation (ASCT). However, individual sensitivity to melphalan varies, and many patients experience severe toxicities. Prolonged severe neutropenia is one of the most severe toxicities and contributes to potentially life-threatening infections and failure of ASCT. Granulocyte-colony stimulating factor (G-CSF) is given to stimulate neutrophil proliferation after melphalan ...

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.

Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant.

The multifactorial mechanisms associated with radical reductions in HIV-1 reservoirs after allogeneic hematopoietic stem cell transplant (allo-HSCT), including a case of HIV cure, are not fully understood.


Advertisement
Quick Search
Advertisement
Advertisement